Sudeep Pharma Limited
Sudeep Pharma Limited (SUDEEPPHRM) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Commodities›Chemicals›Chemicals & Petrochemicals›Specialty Chemicals
sudeepgroup.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-02
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Sales | 163 Cr | 172 Cr | 182 Cr | 158 Cr |
| Operating expenses (approx.) | 107 Cr | 112 Cr | 120 Cr | 103 Cr |
| EBITDA | 55 Cr | 60 Cr | 63 Cr | 55 Cr |
| OPM % | 34.1% | 34.8% | 34.3% | 34.7% |
| Other income | 10 Cr | 7 Cr | 6 Cr | 5 Cr |
| Interest | 2 Cr | 1 Cr | 2 Cr | 2 Cr |
| Depreciation | 4 Cr | 4 Cr | 4 Cr | 4 Cr |
| Profit before tax | 60 Cr | 62 Cr | 63 Cr | 54 Cr |
| Tax % | 21.4% | 22.8% | 22.6% | 25.2% |
| Net profit | 47 Cr | 48 Cr | 49 Cr | 41 Cr |
| EPS (₹) | ₹4.20 | ₹4.29 | ₹4.38 | ₹3.59 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2026 | TTM |
|---|---|---|
| Sales | 642 Cr | Sign in for TTM |
| Operating expenses (approx.) | 420 Cr | Sign in for TTM |
| EBITDA | 222 Cr | Sign in for TTM |
| OPM % | 34.6% | Sign in for TTM |
| Other income | 29 Cr | Sign in for TTM |
| Interest | 8 Cr | Sign in for TTM |
| Depreciation | 15 Cr | Sign in for TTM |
| Profit before tax | 228 Cr | Sign in for TTM |
| Tax % | 23.6% | Sign in for TTM |
| Net profit | 174 Cr | Sign in for TTM |
| EPS (₹) | ₹15.50 | Sign in for TTM |
| Dividend payout % | 0.0% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2026 |
|---|---|
| Equity capital | 11 Cr |
| Reserves | 872 Cr |
| Borrowings | 148 Cr |
| Other liabilities | 128 Cr |
| Total liabilities | 1,175 Cr |
| Fixed assets (net) | 224 Cr |
| CWIP | 178 Cr |
| Investments | 0 Cr |
| Loans & advances | 0.29 Cr |
| Inventories | 216 Cr |
| Trade receivables | 228 Cr |
| Cash & bank | 27 Cr |
| Other assets | 302 Cr |
| Total assets | 1,175 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2026 |
|---|---|
| Cash from operating activity | 70 Cr |
| Cash from investing | -327 Cr |
| Cash from financing | 247 Cr |
| Net cash flow | -10 Cr |
| Free cash flow (OCF − Capex) | -49 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2026 |
|---|---|
| ROCE % | 22.5% |
| ROE % | 19.3% |
| Debtor days | 129 |
| Inventory days | 292 |
| Days payable | 92 |
| Cash conversion cycle | 328 |
| Debt / equity | 0.17 |
| Current ratio | 3.09 |
| Net debt / EBITDA | 0.55 |
Compare with peers
Loading peers…